Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 72, Issue 3, 2015, Pages 436-439.e1

  Papp, Kim ^a   Menter, Alan ^b   Strober, Bruce ^a,c   Kricorian, Greg ^d   Thompson, Elizabeth H Z ^d   Milmont, Cassandra E ^d   Nirula, Ajay ^d   Klekotka, Paul ^d  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

Author keywords

biologic; brodalumab; plaque psoriasis; psoriatic arthritis; quality of life; randomized controlled trial

Indexed keywords

ALEFACEPT; BIOLOGICAL PRODUCT; BRODALUMAB; EFALIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PHASE 2 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SYMPTOM INVENTORY; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; PSORIASIS; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84925356093     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.10.026     Document Type: Article

References (6)

1. K.A. Papp, R.G. Langley, and M. Lebwohl Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
2. C. Ritchlin, P. Rahman, and A. Kavanaugh Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumor necrosis factor therapy: 6-month and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled, randomized PSUMMIT 2 trial Ann Rheum Dis 73 2014 990 999
3. C.E. Griffiths, B.E. Strober, and P. van de Kerkhof Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
4. K.A. Papp, C. Leonardi, and A. Menter Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N Engl J Med 366 2012 1181 1189
5. A.Y. Finlay, and G.K. Khan Dermatology Life Quality Index (DLQI)-A simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
6. M.L. Martin, K.P. McCarrier, and C.F. Chiou Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity J Dermatolog Treat 24 2013 255 260